Výsledky vyhledávání - Thomas A. Mavrakanas
- Zobrazuji výsledky 1 - 10 z 10
-
1
-
2
Cardiovascular complications in chronic dialysis patients Autor Thomas A. Mavrakanas, David M. Charytan
Vydáno 2016Revisão -
3
-
4
-
5
-
6
-
7
Outcomes with revascularization and medical therapy in patients with coronary disease and chronic kidney disease: A meta-analysis Autor Alexandre Leszek, Lauriane Poli, Stéphanie Zbinden, Lucas C. Godoy, Jean‐Luc Reny, Michael E. Farkouh, David M. Charytan, Thomas A. Mavrakanas
Vydáno 2022Revisão -
8
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials Autor Sheldon W. Tobe, Thomas A. Mavrakanas, Harpreet S. Bajaj, Adeera Levin, Navdeep Tangri, April Slee, Brendon L. Neuen, Vlado Perkovic, Kenneth W. Mahaffey, Wally Rapattoni, Fernando G. Ang
Vydáno 2024Artigo -
9
Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents Autor Thomas A. Mavrakanas, Yiannis S. Chatzizisis, Karim Gariani, Larry S. Dean, Giuseppe Gargiulo, Gérard Helft, Martine Gilard, Fausto Feres, Ricardo A. Costa, Marie-Claude Morice, Jean‐Louis Georges, Marco Valgimigli, Deepak L. Bhatt, Laura Mauri, David M. Charytan
Vydáno 2019Revisão -
10
Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline Autor Linan Zeng, Michael Walsh, Gordon Guyatt, Reed Siemieniuk, David Collister, Michelle Booth, Paul Brown, Lesha Farrar, Mark Farrar, Tracy Firth, Lynn A. Fussner, Karin Kilian, Mark A. Little, Thomas A. Mavrakanas, Reem A. Mustafa, Maryam Piram, Lisa K. Stamp, Yingqi Xiao, Lyubov Lytvyn, Thomas Agoritsas, Per Olav Vandvik, Alfred Mahr
Vydáno 2022Artigo
Vyhledávací nástroje:
Související témata
Internal medicine
Medicine
Confidence interval
Cardiology
Hazard ratio
Intensive care medicine
Kidney disease
Atrial fibrillation
Dialysis
Engineering
Incidence (geometry)
Mechanical engineering
Myocardial infarction
Optics
Physics
Randomized controlled trial
Relative risk
Stroke (engine)
Warfarin
Acute kidney injury
Adverse effect
Apixaban
Coronary artery disease
Diabetes mellitus
Endocrinology
Heart failure
Meta-analysis
Pathology
Pharmacology
Rivaroxaban